



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

29<sup>th</sup> May 2023

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Sub: Disclosure of Related Party Transactions pursuant to SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of Related Party Transactions for the half year ended on March 31, 2023.

This is for your information and record

Thanking you

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

**DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED MARCH 31, 2023**  
(In accordance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

(Amount in INR Million)

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee* (rounded off Rs.in Millions )	Value of transaction during the reporting period (rounded off Rs.In Millions)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance as on 01/10/2022	Closing balance as on 31/03/2023	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Natco Pharma Limited		Time Cap Overseas Limited, Mauritius		Subsidiary Company	Investment in Equity Shares	*	-									
2	Natco Pharma Limited		Natco Pharma (Canada) Inc. Canada		Subsidiary Company	Sale of Products	*	663.65	144.66	-							
						Advance Received				105.34							
3	Natco Pharma Limited		Natco Pharma Asia Pte Ltd, Singapore		Subsidiary Company	Interest income on Loan	-	-									
						Repayment of Loan given	-	-									
						Interest receivable	-	-									
						Interest Received	-	-									
						Sale of Products	*	68.77	0	34.56							
						Purchases	-	-									
4	Natco Pharma Limited		Natcofarma Do Brasil Ltda., Brazil		Stedp down Subsidiary Company	Sale of Products	*	419.59	259.79	423.09							
						Corporate Guarantee Given	-	-	299	-							
						Financial Gurantee Liability	-	-	5.67	1.00							
5	Natco Pharma Limited		Natco Pharma Australia Pty Ltd., Australia		Subsidiary Company	Investment in Equity Shares	*	329.36									
6	Natco Pharma Limited		Natco Pharma Inc., United States of America		Subsidiary Company	Investment in Equity Shares	*	329.36									
7	Natco Pharma Limited		NATCO Pharma USA LLC (Formerly known as Dash Pharmaceuticals LLC), United States of America		Subsidiary Company	Sale of Products	*	56.40	-	48.06							
						Reimbursement of expense	*	1.15	-								
8	Natco Pharma Limited		Natco Lifesciences Philippines Inc., Philippines		Subsidiary Company	Investment in Equity Shares	-										
						Sale of Products	*	5.02	7.76	10.83							
						Interrest income on Loan	*	0.13	0.06	0.06							
						Loan given	-	-	4.89	4.93							
9	Natco Pharma Limited		Time Cap Pharma Labs Private Limited		Entities in which Directors have control or have significant influence	Rental Expense	3.30	3.30	0	0							
10	Natco Pharma Limited		Natco Trust		Entities in which Directors have control or have significant influence	Contribution to CSR Activities	20.50	20.50									
						Donations	15.50	15.50									
						Rental Income	0.03	0.03									
11	Natco Pharma Limited		V C Nannapaneni		Key Managerial Personnel	Managerial Remuneration	12.00	12.00	0.78	0.51							
						Leave encashment	0.94	0.94									
						Rental Expense	1.50	1.50									
12	Natco Pharma Limited		Rajeev Nannapaneni		Key Managerial Personnel	Managerial Remuneration	11.06	11.06	0.77	0.40							
						Leave encashment	0.86	0.86									
						Rental Expense	1.50	1.50									
13	Natco Pharma Limited		Potluri Prasad Sivaramakrishna		Key Managerial Personnel	Managerial Remuneration	10.76	10.76	0.74	0.64							
						Leave encashment	0.54	0.54									
						Interest received	0.03	0.03									
						Loan repaid	0.42	0.42	0.39	-							
14	Natco Pharma Limited		Dr.Lingarao Donthineni		Key Managerial Personnel	Managerial Remuneration	23.86	23.86	0.74	0.71							
						Leave encashment	0.54	0.54									
						Interest Income on Loan	2.00	2.00									
						Loan repaid including interest	7.80	7.80	28.57	22.77							
15	Natco Pharma Limited		Dr. Pavan Bhat Ganapati		Key Managerial Personnel	Managerial Remuneration	27.51	27.51	0.61	5.17							

**DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED MARCH 31, 2023**  
(In accordance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

(Amount in INR Million)

S. No	Details of the party (listed entity /subsidiary) entering into the transaction					Type of related party transaction	Value of the related party transaction as approved by the audit committee* (rounded off Rs.in Millions )	Value of transaction during the reporting period (rounded off Rs.In Millions)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance as on 01/10/2022	Closing balance as on 31/03/2023	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
						Leave encashment	0.58	0.58										
16	Natco Pharma Limited		S V V N Appa Rao		Chief Financial Officer	Managerial remuneration	9.14	9.14	0.38	0.42								
						Leave encashment	0.26	0.26										
17	Natco Pharma Limited		Venkat Ramesh Chekuri		Company Secretary	Managerial remuneration	0.83	0.83	0.06	0.06								
18	Natco Pharma Limited		Govinda Prasad Dasu		Independent Director	Sitting fee	*	0.28										
19	Natco Pharma Limited		Leela Digumarti		Independent Director	Sitting fee	*	0.27										
20	Natco Pharma Limited		Umamaheshwarrao Naidu Madireddi		Independent Director	Sitting fee	*	0.25										
21	Natco Pharma Limited		Sreerama Murthy Gubbala		Independent Director	Sitting fee	*	0.43										
22	Natco Pharma Limited		Venkateswara Rao Thallapaka		Independent Director	Sitting fee	*	0.30										

Note: 1. \*As per the provisions of the Companies Act, 2013 and/or approval of the Audit Committee or Board of Directors or shareholders as applicable  
2. The PAN details are not to be included in the disclosure pursuant to guidance note issued by the stock exchanges.  
3. Amounts have been rounded off to nearest million in financial statements whereas in the above statement, the company provided values in two digits.